Depakote
(divalproex sodium)PreclinicalSmall molecule
TevaDivalproex sodium is used to treat seizures in epilepsy, prevent migraine headaches, and manage mood swings in bipolar disorder. It works by stabilizing electrical activity in the brain and nerves.[1] Depakote is currently being investigated across 10 indications[3], with its most advanced program in Preclinical.[1]
Depakote is one of 166 small molecule programs targeting Generalized non-motor (absence) seizure. It is currently in Preclinical.
10
Indications
46
Total Trials
0
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
120 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Aticaprant
Johnson & JohnsonPhase 3
Selective Serotonin Reuptake Inhibitor
Johnson & JohnsonPhase 3
Azetukalner
XXenon Pharmaceuticals Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fasting Conditions8 trials
Show 5 more trials
Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions
Completed·—·Phase 1·NCT01581775·54 enrolled
Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions
Completed·—·Phase 1·NCT01055938·34 enrolled
Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions
Completed·—·Phase 1·NCT01132170·34 enrolled
Bipolar Disorder5 trials
Bipolar I Disorder2 trials
Fed2 trials
Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions
Completed·—·Phase 1·NCT01132196·34 enrolled
Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions
Completed·—·Phase 1·NCT01581788·54 enrolled
22 more indications
Effectiveness2 trials
Epilepsy2 trials
Migraine2 trials
Bipolar Depression1 trial
ART1 trial
Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition
Completed·—·Phase 1·NCT01056627·34 enrolled
Attention Deficit Hyperactivity Disorder1 trial
Combination Therapy1 trial
Schizoaffective Disorder1 trial
Schizophrenia1 trial
Anxiety1 trial
Autism Spectrum Disorder1 trial
Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium
Withdrawn·—·Phase 2·NCT02094651
Acute Lymphoblastic Leukemia1 trial
Solid Tumor, Adult1 trial
Unspecified3 trials
Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)
Completed·—·Phase 1·NCT01132183·34 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for divalproex sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]